Use of vasopressin in persistent pulmonary hypertension of the newborn: A case series.
SAGE Open Med Case Rep
; 10: 2050313X221102289, 2022.
Article
em En
| MEDLINE
| ID: mdl-35693924
ABSTRACT
Treatment of neonates with persistent pulmonary hypertension of newborn includes optimization of ventilatory support, use of pulmonary vasodilators, and/or inotropic support. If refractory to this management, some may require extracorporeal membrane oxygenation. We describe a case series of 10 neonates with refractory persistent pulmonary hypertension of newborn treated with vasopressin in a single tertiary center. Mean initiation time of vasopressin was at 30 h of life with a dose ranging from 10 to 85 milliunits/kg/h. Oxygenation index decreased after 12 h of vasopressin exposure (25 to 11) and mean arterial pressure improved after 1 h (45 to 58 mm Hg). Extracorporeal membrane oxygenation was averted in 50% of the cases with transient hyponatremia as the only notable side effect. Although our findings are exploratory and further research is needed to establish safety and efficacy, our experience suggests that vasopressin may have rescue properties in the management of refractory persistent pulmonary hypertension of newborn.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
SAGE Open Med Case Rep
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos